Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau

Endocrine and Neuroendocrine Tumors (NET)Skin Cancer

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

healthbook TIMES Oncology Hematology

Zihlera D, Vollmera K, Cozzio A

doi: 10.36000/hbT.OH.2019.01.003

Gastrointestinal Cancer

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

healthbook Times Oncology Hematology

Palmarocchi MC, Merlo E, Cefali M, De Dosso S

doi: 10.36000/hbT.OH.2021.07.029

Genitourinary CancerRadio-Oncology

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

Clin Cancer Res.

Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB

doi: 10.1158/

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Genitourinary CancerRadio-Oncology

Improving the prognostic value of disease specific Graded Prognostic Assessment (ds-GPA) model for renal cell carcinoma by incorporation of Cumulative Intracranial Tumor Volume (CITV)

World Neurosurg.

Ali MA, Hirshman BR, Wilson B, Schupper AJ, Joshi R, Proudfoot JA, Goetsch SJ, Alksne JF, Ott K, Aiyama H, Nagano O, Carter BS, Chiang V, Serizawa T, Yamamoto M, Chen CC

doi: 10.1016/j.wneu.2017.07.109.

Genitourinary CancerRadio-Oncology

Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report

Am J Case Rep.

Wendel C, Campitiello M, Plastino F, Eid N, Hennequin L, Quétin P, Longo R

Breast CancerGastrointestinal Cancer

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma

Hered Cancer Clin Pract.

Kientz C, Joly MO, Faivre L, Clemenson A, Dalac S, Lepage C, Chapusot C, Jacquot C, Schiappa R, Lebrun M

doi: 10.1186/s13053-017-0066-9.

Genitourinary Cancer

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

Eur J Cancer.

Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G

doi: 10.1016/j.ejca.2017.06.030.

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.

Lancet Oncol.

Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, MD, Hawkins RE, Hainsworth JD, Kollmannsberger CK, MD, Logan TF, Puzanov I, Pickering LM, Ryan CW, Protheroe A, Lusk CM, Oberg S, George DJ

doi: 10.1016/

Related content

Long-Term Sustained Disease Control With Immunotherapy in Chemotherapy-Refractory Merkel Cell Carcinoma

Multidisciplinary Approach to a Patient with Acinar Cell Carcinoma, a Rare Pancreatic Malignancy

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

Improving the prognostic value of disease specific Graded Prognostic Assessment (ds-GPA) model for renal cell carcinoma by incorporation of Cumulative Intracranial Tumor Volume (CITV)

Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report

A case report of Muir-Torre syndrome in a woman with breast cancer and MSI-Low skin squamous cell carcinoma

Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies

Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.